{
    "nct_id": "NCT03658772",
    "official_title": "An Open-label, Single-arm, Phase 1b Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembolizumab in Patients With Advanced or Progressive Microsatellite Stable (MSS) Colorectal Cancer (CRC)",
    "inclusion_criteria": "* Male and female adult patients 18 years of age or older on day of signing informed consent.\n* Patients must have a histologically confirmed advanced, metastatic, or progressive Microsatellite Stable (MSS) Colorectal Cancer (CRC) per institutional standards.\n* Patient has received at least two prior lines of therapy for advanced or metastatic CRC, at least one of which included fluorouracil.\n* Highly effective birth control.\n* Measurable disease.\n* Accessible tumor that can be safely accessed for multiple core biopsies and patient is willing to provide tissue from newly obtain biopsies before and during treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Adequate organ function.\n* Able to swallow and absorb oral tablets.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor\n* Current use of NSAIDs, COX-2 inhibitors and aspirin products within 3 days (preferably 7 days) before treatment initiation or at anytime during the study unless used for management of AE.\n* History of severe hypersensitivity reactions to chimeric or humanized antibodies\n* Has received prior systemic anticancer therapy including investigational agents within 4 weeks prior to treatment, or 5 half-lives, whichever is shorter.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Known active CNS metastases and/or carcinomatous meningitis.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* History of non-infectious pneumonitis that required steroids or has current pneumonitis.\n* Active infection requiring systemic therapy.\n* Recent (within the last 12 months) or current GI ulcer, colitis or non-immune colitis.\n* Known history of human immunodeficiency virus (HIV) infection, Hepatitis B, or active Hepatitis C virus infection.\n* Clinically significant (i.e. active) cardiovascular disease\n* Allogeneic tissue/solid organ transplant\n* Medical conditions requiring concomitant administration of strong CYP3A4 or P glycoprotein inhibitors or inducers.",
    "miscellaneous_criteria": "Key"
}